Comparison · NCT02051309-e19b3943
Guanfacine 6mg/Day ER vs Placebo: Rates of Prolonged Smoking Abstinence
Calculated by ConductScience from the counts the trial posted to ClinicalTrials.gov.
2 sourcestrial-comparisons-2026-03-23-0.1.0
Cite this record
ConductScience Library. Guanfacine 6mg/Day ER vs Placebo: Rates of Prolonged Smoking Abstinence. Trial comparisons, record NCT02051309-e19b3943. Release trial-comparisons-2026-03-23-0.1.0, 23 Mar 2026. https://conductscience.org/library/comparisons/NCT02051309-e19b3943
On this page
Measures6
Calculated by ConductScience from the counts the trial posted to ClinicalTrials.gov.
| Measure | Value | 95% interval, lower | 95% interval, upper | Method | Note |
|---|---|---|---|---|---|
| Risk in group 1 | 0.355 | 0.211 | 0.531 | wilson | |
| Risk in group 2 | 0.175 | 0.0875 | 0.319 | wilson | |
| Risk difference, group 1 minus group 2 | 0.18 | -0.0239 | 0.376 | newcombe hybrid score | |
| Risk ratio, group 1 over group 2 | 2.03 | 0.89 | 4.62 | log | |
| Odds ratio, group 1 over group 2 | 2.59 | 0.864 | 7.78 | log | |
| Number needed to treat, for one more participant with the outcome on Guanfacine 6mg/Day ER than on Placebo | 5.56 | from the risk difference interval | the interval includes no difference |
Source ClinicalTrials.gov
Groups2
Group 2 names the comparator: placebo.
| Group | Title | Description | With the outcome | Analysed | ClinicalTrials.gov code |
|---|---|---|---|---|---|
| Group 1 | Guanfacine 6mg/Day ER | Guanfacine 6mg/day extended release~Guanfacine: 6mg/day ER with 3-week lead-in period. Maintained at steady state throughout 8 week treatment phase. After treatment phase, given taper supply of medication. | 11 | 31 | OG000 |
| Group 2 | Placebo | Placebo matching capsule~Placebo | 7 | 40 | OG001 |
Source ClinicalTrials.gov
Outcome
- Type
- PRIMARY
- Title
- Rates of Prolonged Smoking Abstinence
- Description
- Prolonged smoking abstinence defined as no relapse in week 3 to week 8, in participants with available outcome data during weeks 3 to 8.
- Time frame
- Week 3 to week 8 during 8-week treatment phase
- Population
- Participants with available outcome data during weeks 3 to 8.
Source ClinicalTrials.gov
Trial
- Title
- Guanfacine Clinical Trial for Smoking Cessation
- NCT number
- NCT02051309
- Phases
- PHASE2
- Conditions
- Smoking Cessation
- Interventions
- Guanfacine, Placebo
- Lead sponsor
- Yale University
- Results first posted
- 2021-12-29
- Results on ClinicalTrials.gov
- https://clinicaltrials.gov/study/NCT02051309?tab=results
Source ClinicalTrials.gov
Source
- Release
- trial-comparisons-2026-03-23-0.1.0
- Release manifest SHA-256
- f66225897fbf258b57ea10bdacfd0347d3cdfda93f7f5685234b7e06ea36fa57
- AACT copy
- 2026-03-23
- Tables read
- outcome_counts.parquet, outcome_measurements.parquet, outcomes.parquet, reported_event_totals.parquet, reported_events.parquet, result_groups.parquet, studies.parquet, ctgov_trial.parquet
Source ClinicalTrials.gov
Sources 2
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions. The measures are ConductScience's calculation from them.
For software
Read this comparison from software.
The record is JSON. No key.
GET https://conductscience.org/api/comparisons/v1/NCT02051309-e19b3943